Zobrazeno 1 - 6
of 6
pro vyhledávání: '"R Fresquet Molina"'
Autor:
MA Allende Bandres, M Arenere Mendoza, P Gomez Rivas, MA Alcacera Lopez, I Varela Martinez, R Fresquet Molina, A Frutos Perez-Surio, L Cazorla Poderoso, T Salvador Gomez, JM Vinuesa Hernando, MDLR Garcia Osuna
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1aa2031a1de46eb40406f8a62a917a8f
https://doi.org/10.1136/ejhpharm-2023-eahp.174
https://doi.org/10.1136/ejhpharm-2023-eahp.174
Autor:
R Fresquet Molina, JM Vinuesa Hernando, M Zurera Berjaga, Mercedes Gimeno, I Varela Martínez, MA Alcácera López, P Gómez Rivas, R Gracia Piquer
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance The inhibitor of cyclin dependent kinases 4 and 6, palbociclib, was a major advance in the treatment of metastatic breast cancer. Aim and objectives To describe the effectiveness and incidence of neutropenia with palbociclib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::438801231efdb87caa46b6b43ad40ec8
https://doi.org/10.1136/ejhpharm-2021-eahpconf.282
https://doi.org/10.1136/ejhpharm-2021-eahpconf.282
Autor:
V Acín Garcés, C Seral García, JM Vinuesa Hernando, R Gracia Piquer, E Morte Romea, R Fresquet Molina, M. Arenere Mendoza, Mercedes Gimeno
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Clostridium difficile disease (CDD) is the leading cause of infectious diarrhoea in the hospital environment. Aim and objectives The objective was to evaluate the characteristics of patients with CDD prior to the implementat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3796f2514e1159c4379ae27a7905c4d1
https://doi.org/10.1136/ejhpharm-2021-eahpconf.83
https://doi.org/10.1136/ejhpharm-2021-eahpconf.83
Autor:
R Fresquet Molina, V Acín Garcés, M. Arenere Mendoza, Mercedes Gimeno, C Seral García, JM Vinuesa Hernando, E Morte Romea, R Gracia Piquer
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Clostridium difficile disease (CDD) is the main cause of nosocomial diarrhoea. Aim and objectives To evaluate the adequacy of treatment of CDD prior to implementation of the checklist for the diagnosis and treatment of CDD.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f795338947b5527aaa91d2797e8ad479
https://doi.org/10.1136/ejhpharm-2021-eahpconf.80
https://doi.org/10.1136/ejhpharm-2021-eahpconf.80
Autor:
T Salvador Gómez, R Fresquet Molina, O Horna Oreja, MA Alcácera López, M Gimeno Gracia, JM Vinuesa Hernando, A Frutos Perez-Surio, R Gracia Piquer, FJ Campos Montellano, M Galindo Allueva
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Adalimumab and etanercept are two of the most used biologic drugs worldwide in a variety of chronic diseases. The introduction of biosimilar drugs (BS) for both has revolutionised the market and may enable more patients to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13a5604968f3cdb2b89a6ca678b4f7d9
https://doi.org/10.1136/ejhpharm-2020-eahpconf.259
https://doi.org/10.1136/ejhpharm-2020-eahpconf.259
Autor:
MJ Nebot Villacampa, MA Alcácera López, JM Vinuesa Hernando, I Varela Martínez, R Gracia Piquer, T Salvador Gómez, M. Arenere Mendoza, R Fresquet Molina, FJ Campos Montellano, M Galindo Allueva
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Since the first biosimilar drug was authorised, medicine agencies have promoted their use. However, interchangeability or switching are different in each country, creating disparity in their use. Aim and objectives To measur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac8137e643d86d9020a85d04826d624a
https://doi.org/10.1136/ejhpharm-2020-eahpconf.258
https://doi.org/10.1136/ejhpharm-2020-eahpconf.258